It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Remarkable deregulation of microRNAs has been demonstrated in epithelial ovarian cancer (EOC). In particular, some of the let-7 miRNA family members have been proposed as tumor suppressors. Here, we explored the functional roles of let-7g in EOC. The ectopic overexpression of let-7g in OVCAR3 and HEY-A8 EOC cells induced i) a down-regulation of c-Myc and cyclin-D2 thus promoting cell cycle arrest, ii) a reduction of Vimentin, Snail and Slug thus counteracting the progression of epithelial to mesenchymal transition, iii) a chemosensitization to cis-platinum treatment. Next, analysis of human EOC tissues revealed that let-7g expression was significantly reduced in tumor tissue specimens of patients with EOC compared to their non-tumor counterparts (p = 0.0002). Notably, low let-7g tissue levels were significantly associated with acquired chemoresistance of patients with late-stage of EOC (n = 17, p = 0.03194). This finding was further validated in the serum samples collected from the same cohort of patients (n = 17, p = 0.003). To conclude, we demonstrate that let-7g acts as tumor suppressor and might be used to disable EOC tumor progression and chemoresistance to cis-platinum-based chemotherapy. Furthermore, we propose that decreased expression of let-7g could serve as a tissue and serum biomarker able to predict the chemo-resistant features of EOC patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 “Magna Græcia” University of Catanzaro, Campus Salvatore Venuta -Viale Europa, Research Center of Biochemistry and Advanced Molecular Biology, Department of Experimental and Clinical Medicine, Catanzaro, Italy (GRID:grid.411489.1) (ISNI:0000 0001 2168 2547); University Magna Graecia of Catanzaro, Campus Salvatore Venuta -Viale Europa, Department of Experimental and Clinical Medicine, Catanzaro, Italy (GRID:grid.411489.1) (ISNI:0000 0001 2168 2547)
2 Klinikum rechts der Isar, Department of Regenerative Medicine in Cardiovascular Disease, Ismaningerstr 22, Munich, Germany (GRID:grid.15474.33) (ISNI:0000 0004 0477 2438)
3 University Magna Graecia of Catanzaro, Campus Salvatore Venuta -Viale Europa, Department of Experimental and Clinical Medicine, Catanzaro, Italy (GRID:grid.411489.1) (ISNI:0000 0001 2168 2547)
4 Unit of Obstetrics and Gynaecology, “Magna Graecia” University of Catanzaro, Catanzaro, Italy (GRID:grid.411489.1) (ISNI:0000 0001 2168 2547)
5 University of Naples “Federico II”, Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, Naples, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X)
6 University Magna Graecia of Catanzaro, Campus Salvatore Venuta -Viale Europa, Department of Experimental and Clinical Medicine, Catanzaro, Italy (GRID:grid.411489.1) (ISNI:0000 0001 2168 2547); University Magna Graecia of Catanzaro, Campus Salvatore Venuta -Viale Europa, Interdepartmental Center of Services (CIS), Catanzaro, Italy (GRID:grid.411489.1) (ISNI:0000 0001 2168 2547)